Nurix Therapeutics (NRIX) experienced a stock decline following the release of new data from its Phase 1a/b clinical trial for bexobrutideg (NX-5948), a treatment targeting B-cell malignancies. Despite this, the trial showcased impressive efficacy, with response rates of 80.9% in patients with chronic lymphocytic leukemia and 84.2% in those with Waldenström Macroglobulinemia. Building on these results, Nurix plans to proceed with pivotal trials within the year.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.